Ontario's Health Technologies Fund now accepting applications
July 4, 2016, TORONTO - Ontario's $20 million Health Technologies Fund (HTF) is open for business.
Announced in May by William Charnetski, Ontario's Chief Health Innovation Strategist, the Fund will support the development of leading, market-ready, made-in-Ontario health technologies by accelerating prototyping, evaluation, adoption and diffusion in the Ontario health care sector.
Sernova Increases Private Placement to $4,200,000
June 29, 2016, London ON – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the “Units”) at $0.25 per Unit, to accommodate additional over-subscriptions (see news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement).
Sernova Announces $2,000,000 First Closing of Private Placement - Due to Oversubscription, Offering Increased to $3,750,000
June 27, 2016 LONDON, ONTARIO Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is closing today $2,000,000 of its non-brokered private placement announced on June 21, 2016. In addition, as the Company has received over-subscriptions of $1,650,000, it is increasing the total amount of the non-brokered private placement offering to $3,750,000 for a total offering of 15,000,000 units (the “Units”) at $0.25 per Unit. The Company plans to close the balance of the placement, Thursday, June 30th, 2016.
Sernova Announces Non-brokered Private Placement - Net proceeds to fund collaborations and a US-based clinical trial
June 21, 2016 LONDON, ONTARIO – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announced today that it has arranged a non-brokered private placement for gross proceeds of $2,000,000. The private placement consists of 8,000,000 units (the “Units”) at a price of $0.25 per Unit.
Canadian Manufacturers & Exporters Article: Valeant manufacturing expansion a Canadian reshoring success
Canadian Manufacturers & Exporters congratulates Valeant Canada on its $27.5 million commitment to expand manufacturing operations in Canada.
For the full article click here
OBIO CAAP Company: Anges Québec members contribute to $530,000 investment in Ovensa
June 8th, 2016 Montreal – Today Anges Québec announced its members are taking a stake in Ovensa,
a biotechnology company. Members of Anges Québec and Aligo Innovation are joining with private investors to inject $530,000 into this Ontario firm, whose new technology delivers therapeutic molecules through oral administration to targeted human tissue, including the brain—a major medical advance.
For the full press release, click here
OBIO CAAP Companies: Highlighted on the Marilyn Denis Show
June 2, 2016 OBIO CAAP companies Eve Medical, Myndtec, and Chipcare were featured on the Marilyn Denis Show this week in a segment focused on Canadian Medical Innovation.
View the video here
OBIO CAAP Company: Perimeter Medical Imaging Receives FDA Clearance for OTIS Optical Tissue Imaging System
May 24, 2016 TORONTO Perimeter Medical Imaging, Inc., an innovative medical imaging company whose mission is to revolutionize tissue removal surgery for surgeons and patients, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its OTISTM 1.0 Optical Coherence Tomography System.
For the full press release, click here
SCIENION inks Joint Development and Marketing pact with AXELA
Berlin, Germany, and Toronto, Canada, MAY 24, 2016: SCIENION AG, a developer of a revolutionary new ultra-low volume liquid handling technology, is pleased to announce that it has entered into a strategic, joint development agreement with AXELA Inc.
For the full press release, click here
OBIO CAAP Company: ChipCare on the Business News Network's "The Disruptors"
ChipCare was featured on BNN's The Disruptors this week. The focus of the interview was ChipCare's differentiation to Theranos, our Series B raise and product pipeline, and our initial focus on low and middle income countries as a smart market entry approach.
Asthma Society of Canada: Fighting for Breath: Severe Asthma Conference
Asthma Society of Canada invites you to register for the Fighting for Breath: Severe Asthma Conference
McMaster University Partners with QoC Health on SMArTVIEW Project
March 3, 2016 QoC Health is a technology partner on McMaster University’s SMArTVIEW project. The $12.3 million project has recently received a $750,000 grant from the eHealth Innovation Partnership Program (eHIPP) from Canadian Institutes of Health Research (CIHR).
Globe & Mail Report On Business Publishes Op-Ed Penned By NACO's Co-Chairs, Ian Bandeen And Bev Tudhop
March 2, 2016 Today, the Globe and Mail Report on Business published an op-ed penned by NACO's Co-Chairs, Ian Bandeen and Bev Tudhop. Titled, "For a Fraction of the Price, Angel Investors Can Pay Huge Dividends".
Self Care Cataysts - Featured Article, Inc. Magazine
Grace Soyao, Founder & CEO, Self Care Catalysts Inc. writes about "Creating Breakthroughs in Entreprneurship" in 4 key steps.
Click here for the full article
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI) is pleased to announce that Fresenius Medical Care, the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).
Focal Healthcare receives 510(k) clearance from the FDA for their targeted prostate biopsy device, Fusion Bx
Toronto, ON – January 29, 2016 – Focal Healthcare Inc.TM, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their targeted prostate biopsy device, Fusion Bx TM.
PlantForm Corporation awarded Government of Canada contract for plant-based production of anti-ricin antibody
lantForm Corporation has received a Government of Canada contract for the plant-based production of an antibody being studied by Defence Research and Development Canada (DRDC) as an antidote to ricin exposure.
Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies
Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies. Sernova resides in the top 3% of TSX Venture Exchange Companies in market performance.
TO Health! announces its evolution and Summit to make Toronto region cluster Top 5 in 10
TORONTO, Feb. 2, 2016 - TO Health! today announced its evolution and strategy to raise the profile of the Toronto Region Human Health and Sciences (HHS) cluster. The vision of the initiative is to make the Toronto region a Top 5 global health science cluster in the next 10 years.
Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma
Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This study of canine lymphoma is based on the success of an initial canine lymphoma study completed in 2014.